Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.
Identifieur interne : 000047 ( PubMed/Corpus ); précédent : 000046; suivant : 000048Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.
Auteurs : Ana Catarina Duarte ; Filipe Vinagre ; Jorge Soares ; Ana CordeiroSource :
- Acta reumatologica portuguesa [ 0303-464X ]
English descriptors
- KwdEn :
- Aged, Azathioprine (therapeutic use), Cyclophosphamide (therapeutic use), Drug Substitution, Female, Humans, Hydroxychloroquine (therapeutic use), Indoles (therapeutic use), Infliximab (therapeutic use), Lung Diseases, Interstitial (drug therapy), Lung Diseases, Interstitial (etiology), Middle Aged, Mycophenolic Acid (therapeutic use), Prednisolone (therapeutic use), Pyridones (therapeutic use), Scleroderma, Systemic (complications), Sjogren's Syndrome (complications), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Azathioprine, Cyclophosphamide, Hydroxychloroquine, Indoles, Infliximab, Mycophenolic Acid, Prednisolone, Pyridones.
- complications : Scleroderma, Systemic, Sjogren's Syndrome.
- drug therapy : Lung Diseases, Interstitial.
- etiology : Lung Diseases, Interstitial.
- Aged, Drug Substitution, Female, Humans, Middle Aged, Treatment Outcome.
Abstract
Interstitial lung disease (ILD) is one of the major causes of morbidity and mortality in patients with connective tissue disease (CTD) and the treatments available until nowadays are in most cases unable to halt disease progression. CTD-ILD pathogenesis includes an initial inflammatory phase, followed by a fibrotic phase, in which extracellular matrix proteins are produced and fibrotic scaring tissue within the lung develops. Steroids and immunosuppressants are the weapons we currently have to treat CTD-ILD. However, mortality rates remain high and identification of new therapeutic targets is crucial. Antifibrotic drugs, which include nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) and due to similar pathogenesis between IPF and CTD-ILD, their use seems attractive in patients with CTD-IL. We report 3 cases of patients with different CTDs, with predominantly fibrotic changes in high resolution computed tomography that progressed despite immunosuppression, and who have attained disease stability after introduction of antifibrotic drugs.
PubMed: 31280278
Links to Exploration step
pubmed:31280278Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.</title><author><name sortKey="Duarte, Ana Catarina" sort="Duarte, Ana Catarina" uniqKey="Duarte A" first="Ana Catarina" last="Duarte">Ana Catarina Duarte</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author><author><name sortKey="Vinagre, Filipe" sort="Vinagre, Filipe" uniqKey="Vinagre F" first="Filipe" last="Vinagre">Filipe Vinagre</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author><author><name sortKey="Soares, Jorge" sort="Soares, Jorge" uniqKey="Soares J" first="Jorge" last="Soares">Jorge Soares</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author><author><name sortKey="Cordeiro, Ana" sort="Cordeiro, Ana" uniqKey="Cordeiro A" first="Ana" last="Cordeiro">Ana Cordeiro</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2019 Apr-Jun</MedlineDate></PubDate></date><idno type="RBID">pubmed:31280278</idno><idno type="pmid">31280278</idno><idno type="wicri:Area/PubMed/Corpus">000047</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000047</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.</title><author><name sortKey="Duarte, Ana Catarina" sort="Duarte, Ana Catarina" uniqKey="Duarte A" first="Ana Catarina" last="Duarte">Ana Catarina Duarte</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author><author><name sortKey="Vinagre, Filipe" sort="Vinagre, Filipe" uniqKey="Vinagre F" first="Filipe" last="Vinagre">Filipe Vinagre</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author><author><name sortKey="Soares, Jorge" sort="Soares, Jorge" uniqKey="Soares J" first="Jorge" last="Soares">Jorge Soares</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author><author><name sortKey="Cordeiro, Ana" sort="Cordeiro, Ana" uniqKey="Cordeiro A" first="Ana" last="Cordeiro">Ana Cordeiro</name><affiliation><nlm:affiliation>Hospital Garcia de Orta.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Acta reumatologica portuguesa</title><idno type="ISSN">0303-464X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Azathioprine (therapeutic use)</term><term>Cyclophosphamide (therapeutic use)</term><term>Drug Substitution</term><term>Female</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Indoles (therapeutic use)</term><term>Infliximab (therapeutic use)</term><term>Lung Diseases, Interstitial (drug therapy)</term><term>Lung Diseases, Interstitial (etiology)</term><term>Middle Aged</term><term>Mycophenolic Acid (therapeutic use)</term><term>Prednisolone (therapeutic use)</term><term>Pyridones (therapeutic use)</term><term>Scleroderma, Systemic (complications)</term><term>Sjogren's Syndrome (complications)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azathioprine</term><term>Cyclophosphamide</term><term>Hydroxychloroquine</term><term>Indoles</term><term>Infliximab</term><term>Mycophenolic Acid</term><term>Prednisolone</term><term>Pyridones</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Scleroderma, Systemic</term><term>Sjogren's Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Substitution</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interstitial lung disease (ILD) is one of the major causes of morbidity and mortality in patients with connective tissue disease (CTD) and the treatments available until nowadays are in most cases unable to halt disease progression. CTD-ILD pathogenesis includes an initial inflammatory phase, followed by a fibrotic phase, in which extracellular matrix proteins are produced and fibrotic scaring tissue within the lung develops. Steroids and immunosuppressants are the weapons we currently have to treat CTD-ILD. However, mortality rates remain high and identification of new therapeutic targets is crucial. Antifibrotic drugs, which include nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) and due to similar pathogenesis between IPF and CTD-ILD, their use seems attractive in patients with CTD-IL. We report 3 cases of patients with different CTDs, with predominantly fibrotic changes in high resolution computed tomography that progressed despite immunosuppression, and who have attained disease stability after introduction of antifibrotic drugs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31280278</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-464X</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><MedlineDate>2019 Apr-Jun</MedlineDate></PubDate></JournalIssue><Title>Acta reumatologica portuguesa</Title><ISOAbbreviation>Acta Reumatol Port</ISOAbbreviation></Journal><ArticleTitle>Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.</ArticleTitle><Pagination><MedlinePgn>161-162</MedlinePgn></Pagination><Abstract><AbstractText>Interstitial lung disease (ILD) is one of the major causes of morbidity and mortality in patients with connective tissue disease (CTD) and the treatments available until nowadays are in most cases unable to halt disease progression. CTD-ILD pathogenesis includes an initial inflammatory phase, followed by a fibrotic phase, in which extracellular matrix proteins are produced and fibrotic scaring tissue within the lung develops. Steroids and immunosuppressants are the weapons we currently have to treat CTD-ILD. However, mortality rates remain high and identification of new therapeutic targets is crucial. Antifibrotic drugs, which include nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) and due to similar pathogenesis between IPF and CTD-ILD, their use seems attractive in patients with CTD-IL. We report 3 cases of patients with different CTDs, with predominantly fibrotic changes in high resolution computed tomography that progressed despite immunosuppression, and who have attained disease stability after introduction of antifibrotic drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Ana Catarina</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Hospital Garcia de Orta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinagre</LastName><ForeName>Filipe</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital Garcia de Orta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Garcia de Orta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordeiro</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Garcia de Orta.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><VernacularTitle>Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.</VernacularTitle></Article><MedlineJournalInfo><Country>Portugal</Country><MedlineTA>Acta Reumatol Port</MedlineTA><NlmUniqueID>0431702</NlmUniqueID><ISSNLinking>0303-464X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>D7NLD2JX7U</RegistryNumber><NameOfSubstance UI="C093844">pirfenidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>G6HRD2P839</RegistryNumber><NameOfSubstance UI="C530716">nintedanib</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="N">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="N">Sjogren's Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31280278</ArticleId><ArticleId IdType="pii">190070</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000047 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000047 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:31280278
|texte= Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:31280278" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |